Suchergebnisse - "Subbiah, Vivek"

PubPharm (147)

1

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

enthalten in: Cancer research communications | 2024

von Subbiah, V. | Coleman, N. | Piha-Paul, S. | +15

2

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Denu, R. | Yang, R. | Lazar, A. | +15

3

TRKing sarcomas for precision medicine : Seek, and ye shall find!

enthalten in: Cancer | 2023

von Moyers, J. | Subbiah, V.

CommentOn: Cancer. 2023 Dec 1;129(23):3772-3782. - PMID 37769113

4

Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma : A Case Series

enthalten in: Clinical lung cancer | 2023

von Fricke, J. | Wang, J. | Gallego, N. | +7

5

The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database : Clinical Implications

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Denu, R. | Moyers, J. | Gouda, M. | +3

6

Lurbinectedin in patients with pretreated endometrial cancer : results from a phase 2 basket clinical trial and exploratory translational study

enthalten in: Investigational new drugs | 2023

von Kristeleit, R. | Leary, A. | Delord, J. | +15

7

RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond

enthalten in: Cancer research | 2023

von Wu, J. | Subbiah, V.

CommentOn: Cancer Res. 2023 Oct 2;83(19):3237-3251. - PMID 37071495

8

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

enthalten in: Cancer discovery | 2023

von Subbiah, V. | Sahai, V. | Maglic, D. | +28

CommentIn: Cancer Discov. 2023 Sep 6;13(9):1964-1965. - PMID 37671472

9

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Subbiah, V. | Chawla, S. | Conley, A. | +16

10

Tumor-Agnostic Precision Medicine from the AACR GENIE Database : Clinical Implications

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Gouda, M. | Nelson, B. | Buschhorn, L. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[15]